SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xcyte Therapies, Inc. (XCYT) -- Ignore unavailable to you. Want to Upgrade?


To: mopgcw who wrote (6)6/22/2004 12:23:46 AM
From: mopgcw  Read Replies (1) | Respond to of 16
 
Xcyte Therapies Rated New `Market Perform' at Piper Jaffrey
2004-05-19 07:27 (New York)

Princeton, New Jersey, May 19 (Bloomberg Data) -- Xcyte Therapies Inc.
(XCYT US) was rated new ``market perform'' in new coverage by analyst Sandeep
Bhatia at Piper Jaffray & Co. The price target is $8.00 per share.